The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

NCT05596968 · clinicaltrials.gov ↗

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation
Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Sorafenib

Sponsor

Nanfang Hospital, Southern Medical University